{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:07:10Z","timestamp":1791929230579,"version":"4.3.4"},"reference-count":226,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100007642","name":"Universit\u00e0 degli Studi di Roma Tor Vergata","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007642","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s40265-024-02086-5","type":"journal-article","created":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T18:02:39Z","timestamp":1727373759000},"page":"1251-1273","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences"],"prefix":"10.1007","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4895-9707","authenticated-orcid":false,"given":"Mario","family":"Cazzola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9358-3799","authenticated-orcid":false,"given":"Clive P.","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3087-9530","authenticated-orcid":false,"given":"Nicola A.","family":"Hanania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0456-069X","authenticated-orcid":false,"given":"Luigino","family":"Calzetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5113-9235","authenticated-orcid":false,"given":"Maria Gabriella","family":"Matera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7801-5040","authenticated-orcid":false,"given":"Paola","family":"Rogliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,26]]},"reference":[{"key":"2086_CR1","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0000000000000600","author":"K Aggarwal","year":"2023","unstructured":"Aggarwal K, Bansal V, Mahmood R, et al. Asthma and cardiovascular diseases: uncovering common ground in risk factors and pathogenesis. Cardiol Rev. 2023. https:\/\/doi.org\/10.1097\/CRD.0000000000000600.","journal-title":"Cardiol Rev"},{"issue":"5","key":"2086_CR2","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s44161-022-00067-z","volume":"1","author":"J Guo","year":"2022","unstructured":"Guo J, Zhang Y, Liu T, et al. Allergic asthma is a risk factor for human cardiovascular diseases. Nat Cardiovas Res. 2022;1(5):417\u201330. https:\/\/doi.org\/10.1038\/s44161-022-00067-z.","journal-title":"Nat Cardiovas Res."},{"issue":"2","key":"2086_CR3","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.amepre.2022.09.010","volume":"64","author":"KE Dodd","year":"2023","unstructured":"Dodd KE, Blackley DJ, Mazurek JM. Cardiovascular disease among adults with work-related asthma, 2012\u20132017. Am J Prev Med. 2023;64(2):194\u2013203. https:\/\/doi.org\/10.1016\/j.amepre.2022.09.010.","journal-title":"Am J Prev Med"},{"issue":"3","key":"2086_CR4","doi-asserted-by":"publisher","first-page":"232","DOI":"10.33963\/KP.a2023.0038","volume":"81","author":"M Cazzola","year":"2023","unstructured":"Cazzola M, Hanania NA, Rogliani P, et al. Cardiovascular disease in asthma patients: from mechanisms to therapeutic implications. Kardiol Pol. 2023;81(3):232\u201341. https:\/\/doi.org\/10.33963\/KP.a2023.0038.","journal-title":"Kardiol Pol"},{"issue":"3","key":"2086_CR5","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.jstrokecerebrovasdis.2015.11.030","volume":"25","author":"LY Wen","year":"2016","unstructured":"Wen LY, Ni H, Li KS, et al. Asthma and risk of stroke: a systematic review and meta-analysis. J Stroke Cerebrovasc Dis. 2016;25(3):497\u2013503. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2015.11.030.","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"6","key":"2086_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0179335","volume":"12","author":"L Wang","year":"2017","unstructured":"Wang L, Gao S, Yu M, Sheng Z, Tan W. Association of asthma with coronary heart disease: a meta analysis of 11 trials. PLoS ONE. 2017;12(6): e0179335. https:\/\/doi.org\/10.1371\/journal.pone.0179335.","journal-title":"PLoS ONE"},{"key":"2086_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.861798","volume":"9","author":"B Zhang","year":"2022","unstructured":"Zhang B, Li ZF, An ZY, et al. Association between asthma and all-cause mortality and cardiovascular disease morbidity and mortality: a meta-analysis of cohort studies. Front Cardiovasc Med. 2022;9: 861798. https:\/\/doi.org\/10.3389\/fcvm.2022.861798.","journal-title":"Front Cardiovasc Med."},{"issue":"10","key":"2086_CR8","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s10654-019-00562-x","volume":"34","author":"A Cepelis","year":"2019","unstructured":"Cepelis A, Brumpton BM, Laugsand LE, et al. Asthma, asthma control and risk of acute myocardial infarction: HUNT study. Eur J Epidemiol. 2019;34(10):967\u201377. https:\/\/doi.org\/10.1007\/s10654-019-00562-x.","journal-title":"Eur J Epidemiol"},{"issue":"1","key":"2086_CR9","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jaip.2017.06.008","volume":"6","author":"PP Hekking","year":"2018","unstructured":"Hekking PP, Amelink M, Wener RR, Bouvy ML, Bel EH. Comorbidities in difficult-to-control asthma. J Allergy Clin Immunol Pract. 2018;6(1):108\u201313. https:\/\/doi.org\/10.1016\/j.jaip.2017.06.008.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"167","key":"2086_CR10","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0202-2022","volume":"32","author":"P Rogliani","year":"2023","unstructured":"Rogliani P, Laitano R, Ora J, Beasley R, Calzetta L. Strength of association between comorbidities and asthma: a meta-analysis. Eur Respir Rev. 2023;32(167): 220202. https:\/\/doi.org\/10.1183\/16000617.0202-2022.","journal-title":"Eur Respir Rev"},{"issue":"4","key":"2086_CR11","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/j.chest.2020.11.053","volume":"159","author":"ME Pollevick","year":"2021","unstructured":"Pollevick ME, Xu KY, Mhango G, et al. The relationship between asthma and cardiovascular disease: an examination of the Framingham Offspring Study. Chest. 2021;159(4):1338\u201345. https:\/\/doi.org\/10.1016\/j.chest.2020.11.053.","journal-title":"Chest"},{"issue":"6","key":"2086_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2024.100907","volume":"17","author":"HG Choi","year":"2024","unstructured":"Choi HG, Kwon MJ, Kim JH, et al. Association between asthma and cardiovascular diseases: a longitudinal follow-up study using a national health screening cohort. World Allergy Organ J. 2024;17(6): 100907. https:\/\/doi.org\/10.1016\/j.waojou.2024.100907.","journal-title":"World Allergy Organ J"},{"issue":"8","key":"2086_CR13","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1136\/thx.2004.026484","volume":"60","author":"JG Schanen","year":"2005","unstructured":"Schanen JG, Iribarren C, Shahar E, et al. Asthma and incident cardiovascular disease: the Atherosclerosis Risk in Communities Study. Thorax. 2005;60(8):633\u20138. https:\/\/doi.org\/10.1136\/thx.2004.026484.","journal-title":"Thorax"},{"issue":"2","key":"2086_CR14","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.rmed.2011.07.021","volume":"106","author":"M Cazzola","year":"2012","unstructured":"Cazzola M, Calzetta L, Bettoncelli G, et al. Cardiovascular disease in asthma and COPD: a population-based retrospective cross-sectional study. Respir Med. 2012;106(2):249\u201356. https:\/\/doi.org\/10.1016\/j.rmed.2011.07.021.","journal-title":"Respir Med"},{"issue":"5","key":"2086_CR15","doi-asserted-by":"publisher","first-page":"2301788","DOI":"10.1183\/13993003.01788-2023","volume":"62","author":"CA Valencia-Hern\u00e1ndez","year":"2023","unstructured":"Valencia-Hern\u00e1ndez CA, Del Greco MF, Sundaram V, Portas L, Minelli C, Bloom CI. Asthma and incident coronary heart disease: an observational and Mendelian randomisation study. Eur Respir J. 2023;62(5):2301788. https:\/\/doi.org\/10.1183\/13993003.01788-2023.","journal-title":"Eur Respir J"},{"issue":"1","key":"2086_CR16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1183\/09031936.00140310","volume":"38","author":"M Cazzola","year":"2011","unstructured":"Cazzola M, Calzetta L, Bettoncelli G, Novelli L, Cricelli C, Rogliani P. Asthma and comorbid medical illness. Eur Respir J. 2011;38(1):42\u20139. https:\/\/doi.org\/10.1183\/09031936.00140310.","journal-title":"Eur Respir J"},{"key":"2086_CR17","doi-asserted-by":"publisher","first-page":"1175890","DOI":"10.3389\/fimmu.2023.1175890","volume":"14","author":"S Wang","year":"2023","unstructured":"Wang S, Liu H, Yang P, et al. Exploring the genetic association of allergic diseases with cardiovascular diseases: a bidirectional Mendelian randomization study. Front Immunol. 2023;14:1175890. https:\/\/doi.org\/10.3389\/fimmu.2023.1175890.","journal-title":"Front Immunol"},{"issue":"10","key":"2086_CR18","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.3390\/biomedicines10102614","volume":"10","author":"M Kreslov\u00e1","year":"2022","unstructured":"Kreslov\u00e1 M, Kirchnerov\u00e1 O, Rajdl D, et al. Bronchial asthma as a cardiovascular risk factor: a prospective observational study. Biomedicines. 2022;10(10):2614. https:\/\/doi.org\/10.3390\/biomedicines10102614.","journal-title":"Biomedicines."},{"issue":"23","key":"2086_CR19","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.026644","volume":"11","author":"MC Tattersall","year":"2022","unstructured":"Tattersall MC, Dasiewicz AS, McClelland RL, et al. Persistent asthma is associated with carotid plaque in MESA. J Am Heart Assoc. 2022;11(23): e026644. https:\/\/doi.org\/10.1161\/JAHA.122.026644.","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"2086_CR20","doi-asserted-by":"publisher","first-page":"2300700","DOI":"10.1183\/13993003.00700-2023","volume":"62","author":"M Cazzola","year":"2023","unstructured":"Cazzola M, Page CP, Matera MG, et al. Revisiting asthma pharmacotherapy: where do we stand and where do we want to go? Eur Respir J. 2023;62(2):2300700. https:\/\/doi.org\/10.1183\/13993003.00700-2023.","journal-title":"Eur Respir J"},{"issue":"42","key":"2086_CR21","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001880","volume":"94","author":"MJ Hung","year":"2015","unstructured":"Hung MJ, Mao CT, Hung MY, Chen TH. Impact of asthma on the development of coronary vasospastic angina: a population-based cohort study. Medicine (Baltimore). 2015;94(42): e1880. https:\/\/doi.org\/10.1097\/MD.0000000000001880.","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"2086_CR22","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/s0002-9149(96)00147-6","volume":"77","author":"Y Sakata","year":"1996","unstructured":"Sakata Y, Komamura K, Hirayama A, et al. Elevation of the plasma histamine concentration in the coronary circulation in patients with variant angina. Am J Cardiol. 1996;77(12):1121\u20136. https:\/\/doi.org\/10.1016\/s0002-9149(96)00147-6.","journal-title":"Am J Cardiol"},{"issue":"7","key":"2086_CR23","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.3390\/biomedicines10071499","volume":"10","author":"S Bazan-Socha","year":"2022","unstructured":"Bazan-Socha S, W\u00f3jcik K, Olchawa M, et al. Increased oxidative stress in asthma-relation to inflammatory blood and lung biomarkers and airway remodeling indices. Biomedicines. 2022;10(7):1499. https:\/\/doi.org\/10.3390\/biomedicines10071499.","journal-title":"Biomedicines"},{"key":"2086_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vph.2017.05.005","volume":"100","author":"MA Incalza","year":"2018","unstructured":"Incalza MA, D\u2019Oria R, Natalicchio A, et al. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. Vascul Pharmacol. 2018;100:1\u201319. https:\/\/doi.org\/10.1016\/j.vph.2017.05.005.","journal-title":"Vascul Pharmacol"},{"issue":"8","key":"2086_CR25","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.bbi.2007.03.009","volume":"21","author":"E Chen","year":"2007","unstructured":"Chen E, Miller GE. Stress and inflammation in exacerbations of asthma. Brain Behav Immun. 2007;21(8):993\u20139. https:\/\/doi.org\/10.1016\/j.bbi.2007.03.009.","journal-title":"Brain Behav Immun"},{"issue":"7","key":"2086_CR26","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41440-023-01319-6","volume":"46","author":"S Hoshide","year":"2023","unstructured":"Hoshide S, Mogi M, Kario K. Sympathetic nervous activation and hypertension. Hypertens Res. 2023;46(7):1636\u20137. https:\/\/doi.org\/10.1038\/s41440-023-01319-6.","journal-title":"Hypertens Res"},{"key":"2086_CR27","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.rmed.2019.04.001","volume":"151","author":"M Cazzola","year":"2019","unstructured":"Cazzola M, Rogliani P, Calzetta L, et al. Bronchodilators in subjects with asthma-related comorbidities. Respir Med. 2019;151:43\u20138. https:\/\/doi.org\/10.1016\/j.rmed.2019.04.001.","journal-title":"Respir Med"},{"key":"2086_CR28","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1183\/2312508X.10027419","volume-title":"Cardiovascular complications of respiratory disorders (ERS Monograph)","author":"J Ora","year":"2020","unstructured":"Ora J, Cavalli F, Cazzola M. Management of patients with asthma or COPD and cardiovascular disease: risks versus benefits. In: Mart\u00ednez-Garc\u00eda MA, P\u00e9pin J-L, Cazzola M, editors. Cardiovascular complications of respiratory disorders (ERS Monograph). Sheffield: European Respiratory Society; 2020. p. 66\u201381. https:\/\/doi.org\/10.1183\/2312508X.10027419."},{"issue":"1","key":"2086_CR29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41533-023-00330-1","volume":"33","author":"ML Levy","year":"2023","unstructured":"Levy ML, Bacharier LB, Bateman E, et al. Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update. NPJ Prim Care Respir Med. 2023;33(1):7. https:\/\/doi.org\/10.1038\/s41533-023-00330-1.","journal-title":"NPJ Prim Care Respir Med."},{"issue":"1","key":"2086_CR30","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/all.14425","volume":"76","author":"I Agache","year":"2021","unstructured":"Agache I, Akdis CA, Akdis M, et al. EAACI biologicals guidelines-recommendations for severe asthma. Allergy. 2021;76(1):14\u201344. https:\/\/doi.org\/10.1111\/all.14425.","journal-title":"Allergy"},{"issue":"18","key":"2086_CR31","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1080\/14656566.2020.1807514","volume":"21","author":"J Ora","year":"2020","unstructured":"Ora J, Calzetta L, Matera MG, et al. Advances with glucocorticoids in the treatment of asthma: state of the art. Expert Opin Pharmacother. 2020;21(18):2305\u201316. https:\/\/doi.org\/10.1080\/14656566.2020.1807514.","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"2086_CR32","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.atherosclerosis.2006.05.019","volume":"192","author":"C Varas-Lorenzo","year":"2007","unstructured":"Varas-Lorenzo C, Rodriguez LA, Maguire A, Castellsague J, Perez-Gutthann S. Use of oral corticosteroids and the risk of acute myocardial infarction. Atherosclerosis. 2007;192(2):376\u201383. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2006.05.019.","journal-title":"Atherosclerosis"},{"issue":"6","key":"2086_CR33","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/j.jaci.2015.07.046","volume":"136","author":"P Lefebvre","year":"2015","unstructured":"Lefebvre P, Duh MS, Lafeuille MH, et al. Acute and chronic systemic corticosteroid-related complications in patients with severe asthma. J Allergy Clin Immunol. 2015;136(6):1488\u201395. https:\/\/doi.org\/10.1016\/j.jaci.2015.07.046.","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"2086_CR34","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1111\/all.13874","volume":"74","author":"M Ekstr\u00f6m","year":"2019","unstructured":"Ekstr\u00f6m M, Nwaru BI, Hasvold P, et al. Oral corticosteroid use, morbidity and mortality in asthma: a nationwide prospective cohort study in Sweden. Allergy. 2019;74(11):2181\u201390. https:\/\/doi.org\/10.1111\/all.13874.","journal-title":"Allergy"},{"issue":"8","key":"2086_CR35","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1136\/hrt.2003.031492","volume":"90","author":"MK Ng","year":"2004","unstructured":"Ng MK, Celermajer DS. Glucocorticoid treatment and cardiovascular disease. Heart. 2004;90(8):829\u201330. https:\/\/doi.org\/10.1136\/hrt.2003.031492.","journal-title":"Heart"},{"issue":"5","key":"2086_CR36","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/s0002-9343(03)00393-0","volume":"115","author":"S Suissa","year":"2003","unstructured":"Suissa S, Assimes T, Brassard P, et al. Inhaled corticosteroid use in asthma and the prevention of myocardial infarction. Am J Med. 2003;115(5):377\u201381. https:\/\/doi.org\/10.1016\/s0002-9343(03)00393-0.","journal-title":"Am J Med"},{"key":"2086_CR37","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/CLEP.S341048","volume":"14","author":"OA Ayodele","year":"2022","unstructured":"Ayodele OA, Cabral HJ, McManus DD, et al. Glucocorticoids and risk of venous thromboembolism in asthma patients aged 20\u201359 years in the United Kingdom\u2019s CPRD 1995\u20132015. Clin Epidemiol. 2022;14:83\u201393. https:\/\/doi.org\/10.2147\/CLEP.S341048.","journal-title":"Clin Epidemiol"},{"issue":"3","key":"2086_CR38","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1378\/chest.07-3126","volume":"134","author":"CA Camargo","year":"2008","unstructured":"Camargo CA, Barr RG, Chen R, et al. Prospective study of inhaled corticosteroid use, cardiovascular mortality, and all-cause mortality in asthmatic women. Chest. 2008;134(3):546\u201351. https:\/\/doi.org\/10.1378\/chest.07-3126.","journal-title":"Chest"},{"key":"2086_CR39","doi-asserted-by":"publisher","first-page":"5337","DOI":"10.12659\/msm.904469","volume":"23","author":"M Podg\u00f3rski","year":"2017","unstructured":"Podg\u00f3rski M, Kupczyk M, Grzelak P, et al. Inhaled corticosteroids in asthma: promoting or protecting against atherosclerosis? Med Sci Monit. 2017;23:5337\u201344. https:\/\/doi.org\/10.12659\/msm.904469.","journal-title":"Med Sci Monit"},{"issue":"3","key":"2086_CR40","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/bcp.12637","volume":"80","author":"PT Daley-Yates","year":"2015","unstructured":"Daley-Yates PT. Inhaled corticosteroids: potency, dose equivalence and therapeutic index. Br J Clin Pharmacol. 2015;80(3):372\u201380. https:\/\/doi.org\/10.1111\/bcp.12637.","journal-title":"Br J Clin Pharmacol"},{"key":"2086_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s41030-017-0043-5","volume":"3","author":"Q Ye","year":"2017","unstructured":"Ye Q, He XO, D\u2019Urzo A. A review on the safety and efficacy of inhaled corticosteroids in the management of asthma. Pulm Ther. 2017;3:1\u201318. https:\/\/doi.org\/10.1007\/s41030-017-0043-5.","journal-title":"Pulm Ther."},{"key":"2086_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2019.101828","volume":"58","author":"MG Matera","year":"2019","unstructured":"Matera MG, Rinaldi B, Calzetta L, Rogliani P, Cazzola M. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids for asthma treatment. Pulm Pharmacol Ther. 2019;58: 101828. https:\/\/doi.org\/10.1016\/j.pupt.2019.101828.","journal-title":"Pulm Pharmacol Ther"},{"issue":"8","key":"2086_CR43","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1164\/rccm.201210-1853PP","volume":"187","author":"HH Raissy","year":"2013","unstructured":"Raissy HH, Kelly HW, Harkins M, Szefler SJ. Inhaled corticosteroids in lung diseases. Am J Respir Crit Care Med. 2013;187(8):798\u2013803. https:\/\/doi.org\/10.1164\/rccm.201210-1853PP.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"2086_CR44","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.pupt.2005.10.008","volume":"20","author":"GA Rossi","year":"2007","unstructured":"Rossi GA, Cerasoli F, Cazzola M. Safety of inhaled corticosteroids: room for improvement. Pulm Pharmacol Ther. 2007;20(1):23\u201335. https:\/\/doi.org\/10.1016\/j.pupt.2005.10.008.","journal-title":"Pulm Pharmacol Ther"},{"issue":"15","key":"2086_CR45","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.3390\/jcm11154491","volume":"11","author":"P Rogliani","year":"2022","unstructured":"Rogliani P, Ora J, Cavalli F, Cazzola M, Calzetta L. Comparing the efficacy and safety profile of triple fixed-dose combinations in COPD: a meta-analysis and IBiS score. J Clin Med. 2022;11(15):4491. https:\/\/doi.org\/10.3390\/jcm11154491.","journal-title":"J Clin Med"},{"issue":"2","key":"2086_CR46","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1124\/dmd.112.046318","volume":"41","author":"CD Moore","year":"2013","unstructured":"Moore CD, Roberts JK, Orton CR, et al. Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes. Drug Metab Dispos. 2013;41(2):379\u201389. https:\/\/doi.org\/10.1124\/dmd.112.046318.","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"2086_CR47","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1021\/acs.biochem.8b0122","volume":"58","author":"I Sevrioukova","year":"2019","unstructured":"Sevrioukova I. Interaction of human drug-metabolizing CYP3A4 with small inhibitory molecules. Biochemistry. 2019;58(7):930\u20139. https:\/\/doi.org\/10.1021\/acs.biochem.8b0122.","journal-title":"Biochemistry"},{"issue":"1","key":"2086_CR48","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2147\/copd.s1516","volume":"3","author":"C Macie","year":"2008","unstructured":"Macie C, Wooldrage K, Manfreda J, et al. Cardiovascular morbidity and the use of inhaled bronchodilators. Int J Chron Obstruct Pulmon Dis. 2008;3(1):163\u20139. https:\/\/doi.org\/10.2147\/copd.s1516.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"4","key":"2086_CR49","doi-asserted-by":"publisher","first-page":"H1205","DOI":"10.1152\/ajpheart.2000.278.4.H1205","volume":"278","author":"FA Dinenno","year":"2000","unstructured":"Dinenno FA, Jones PP, Seals DR, et al. Age-associated arterial wall thickening is related to elevations in sympathetic activity in healthy humans. Am J Physiol Heart Circ Physiol. 2000;278(4):H1205\u201310. https:\/\/doi.org\/10.1152\/ajpheart.2000.278.4.H1205.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"7","key":"2086_CR50","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1038\/s41440-023-01257-3","volume":"46","author":"CJ Lee","year":"2023","unstructured":"Lee CJ, Hwang J, Kang CY, et al. Asthma and increased risk of myocardial infarction and mortality among hypertensive Korean patients. Hypertens Res. 2023;46(7):1694\u2013704. https:\/\/doi.org\/10.1038\/s41440-023-01257-3.","journal-title":"Hypertens Res"},{"issue":"7","key":"2086_CR51","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1164\/rccm.201209-1739PP","volume":"187","author":"M Cazzola","year":"2013","unstructured":"Cazzola M, Page CP, Rogliani P, et al. \u03b22-agonist therapy in lung disease. Am J Respir Crit Care Med. 2013;187(7):690\u20136. https:\/\/doi.org\/10.1164\/rccm.201209-1739PP.","journal-title":"Am J Respir Crit Care Med"},{"key":"2086_CR52","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.rmed.2019.07.018","volume":"155","author":"LE Moore","year":"2019","unstructured":"Moore LE, Kapoor K, Byers BW, et al. Acute effects of salbutamol on systemic vascular function in people with asthma. Respir Med. 2019;155:133\u201340. https:\/\/doi.org\/10.1016\/j.rmed.2019.07.018.","journal-title":"Respir Med"},{"issue":"8","key":"2086_CR53","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1592\/phco.31.8.748","volume":"31","author":"EM Snyder","year":"2011","unstructured":"Snyder EM, Wong EC, Foxx-Lupo WT, et al. Effects of an inhaled \u03b22-agonist on cardiovascular function and sympathetic activity in healthy subjects. Pharmacotherapy. 2011;31(8):748\u201356. https:\/\/doi.org\/10.1592\/phco.31.8.748.","journal-title":"Pharmacotherapy"},{"issue":"1","key":"2086_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pupt.2009.10.001","volume":"23","author":"MG Matera","year":"2010","unstructured":"Matera MG, Martuscelli E, Cazzola M. Pharmacological modulation of \u03b2-adrenoceptor function in patients with coexisting chronic obstructive pulmonary disease and chronic heart failure. Pulm Pharmacol Ther. 2010;23(1):1\u20138. https:\/\/doi.org\/10.1016\/j.pupt.2009.10.001.","journal-title":"Pulm Pharmacol Ther"},{"issue":"3","key":"2086_CR55","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1161\/01.res.59.3.297","volume":"59","author":"MR Bristow","year":"1986","unstructured":"Bristow MR, Ginsburg R, Umans V, et al. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res. 1986;59(3):297\u2013309. https:\/\/doi.org\/10.1161\/01.res.59.3.297.","journal-title":"Circ Res"},{"issue":"15","key":"2086_CR56","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1007\/s40265-013-0120-5","volume":"73","author":"MG Matera","year":"2013","unstructured":"Matera MG, Calzetta L, Cazzola M. \u03b2-Adrenoceptor modulation in chronic obstructive pulmonary disease: present and future perspectives. Drugs. 2013;73(15):1653\u201363. https:\/\/doi.org\/10.1007\/s40265-013-0120-5.","journal-title":"Drugs"},{"issue":"4","key":"2086_CR57","first-page":"651","volume":"51","author":"OE Brodde","year":"1999","unstructured":"Brodde OE, Michel MC. Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev. 1999;51(4):651\u201390.","journal-title":"Pharmacol Rev"},{"key":"2086_CR58","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1183\/2312508X.10028519","volume-title":"Cardiovascular complications of respiratory disorders (ERS Monograph)","author":"MG Matera","year":"2020","unstructured":"Matera MG, Panettieri RA Jr. \u03b22-adrenoceptor modulation in COPD and its potential impact on cardiovascular comorbidities. In: Mart\u00ednez-Garc\u00eda MA, P\u00e9pin J-L, Cazzola M, editors. Cardiovascular complications of respiratory disorders (ERS Monograph). Sheffield: European Respiratory Society; 2020. p. 229\u201337. https:\/\/doi.org\/10.1183\/2312508X.10028519."},{"issue":"1","key":"2086_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MCP.0b013e328333def8","volume":"16","author":"NA Hanania","year":"2010","unstructured":"Hanania NA, Dickey BF, Bond RA. Clinical implications of the intrinsic efficacy of beta-adrenoceptor drugs in asthma: full, partial and inverse agonism. Curr Opin Pulm Med. 2010;16(1):1\u20135. https:\/\/doi.org\/10.1097\/MCP.0b013e328333def8.","journal-title":"Curr Opin Pulm Med"},{"issue":"2","key":"2086_CR60","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ijcard.2014.07.087","volume":"176","author":"WL Chan","year":"2014","unstructured":"Chan WL, Yang KP, Chao TF, et al. The association of asthma and atrial fibrillation\u2014a nationwide population-based nested case\u2013control study. Int J Cardiol. 2014;176(2):464\u20139. https:\/\/doi.org\/10.1016\/j.ijcard.2014.07.087.","journal-title":"Int J Cardiol"},{"issue":"6","key":"2086_CR61","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1378\/chest.125.6.2309","volume":"125","author":"SR Salpeter","year":"2004","unstructured":"Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004;125(6):2309\u201321. https:\/\/doi.org\/10.1378\/chest.125.6.2309.","journal-title":"Chest"},{"issue":"7","key":"2086_CR62","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.amjcard.2008.05.029","volume":"102","author":"P Thottathil","year":"2008","unstructured":"Thottathil P, Acharya J, Moss AJ, et al. Risk of cardiac events in patients with asthma and long-QT syndrome treated with \u03b22-agonists. Am J Cardiol. 2008;102(7):871\u20134. https:\/\/doi.org\/10.1016\/j.amjcard.2008.05.029.","journal-title":"Am J Cardiol"},{"issue":"3","key":"2086_CR63","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.ejcdt.2014.03.010","volume":"63","author":"HA Mohammad","year":"2014","unstructured":"Mohammad HA, Abdulfttah MT, Abdulazez AO, et al. A study of electrolyte disturbances in patients with chronic stable asthma and with asthma attacks. Egypt J Chest Dis Tuberc. 2014;63(3):529\u201334. https:\/\/doi.org\/10.1016\/j.ejcdt.2014.03.010.","journal-title":"Egypt J Chest Dis Tuberc."},{"issue":"7","key":"2086_CR64","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1097\/HJH.0b013e32832af68d","volume":"27","author":"B Zhang","year":"2009","unstructured":"Zhang B, de Vries F, Setakis E, van Staa TP. The pattern of risk of myocardial infarction in patients taking asthma medication: a study with the General Practice Research Database. J Hypertens. 2009;27(7):1485\u201392. https:\/\/doi.org\/10.1097\/HJH.0b013e32832af68d.","journal-title":"J Hypertens"},{"issue":"5","key":"2086_CR65","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/j.1472-8206.2010.00859.x","volume":"24","author":"T Clausen","year":"2010","unstructured":"Clausen T. Hormonal and pharmacological modification of plasma potassium homeostasis. Fundam Clin Pharmacol. 2010;24(5):595\u2013605. https:\/\/doi.org\/10.1111\/j.1472-8206.2010.00859.x.","journal-title":"Fundam Clin Pharmacol"},{"key":"2086_CR66","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.3389\/fphys.2018.01500","volume":"9","author":"J Skogestad","year":"2018","unstructured":"Skogestad J, Aronsen JM. Hypokalemia-induced arrhythmias and heart failure: new insights and implications for therapy. Front Physiol. 2018;9:1500. https:\/\/doi.org\/10.3389\/fphys.2018.01500.","journal-title":"Front Physiol"},{"issue":"6","key":"2086_CR67","doi-asserted-by":"publisher","first-page":"H3043","DOI":"10.1152\/ajpheart.01312.2006","volume":"292","author":"S Poelzing","year":"2007","unstructured":"Poelzing S, Veeraraghavan R. Heterogeneous ventricular chamber response to hypokalemia and inward rectifier potassium channel blockade underlies bifurcated T wave in guinea pig. Am J Physiol Heart Circ Physiol. 2007;292(6):H3043\u201351. https:\/\/doi.org\/10.1152\/ajpheart.01312.2006.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"3","key":"2086_CR68","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.116.004667","volume":"10","author":"JN Weiss","year":"2017","unstructured":"Weiss JN, Qu Z, Shivkumar K. Electrophysiology of hypokalemia and hyperkalemia. Circ Arrhythm Electrophysiol. 2017;10(3): e004667. https:\/\/doi.org\/10.1161\/CIRCEP.116.004667.","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"2","key":"2086_CR69","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/BF03160909","volume":"3","author":"GP Daubert","year":"2007","unstructured":"Daubert GP, Mabasa VH, Leung VW, et al. Acute clenbuterol overdose resulting in supraventricular tachycardia and atrial fibrillation. J Med Toxicol. 2007;3(2):56\u201360. https:\/\/doi.org\/10.1007\/BF03160909.","journal-title":"J Med Toxicol"},{"issue":"1","key":"2086_CR70","doi-asserted-by":"publisher","first-page":"73","DOI":"10.5847\/wjem.j.1920-8642.2021.01.012","volume":"12","author":"B Zheng","year":"2021","unstructured":"Zheng B, Yadav K. Acute salbutamol toxicity in the emergency department: a case report. World J Emerg Med. 2021;12(1):73\u20135. https:\/\/doi.org\/10.5847\/wjem.j.1920-8642.2021.01.012.","journal-title":"World J Emerg Med"},{"issue":"8","key":"2086_CR71","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1001\/jamacardio.2018.1901","volume":"3","author":"A Cepelis","year":"2018","unstructured":"Cepelis A, Brumpton BM, Malmo V, et al. Associations of asthma and asthma control with atrial fibrillation risk: results from the Nord-Tr\u00f8ndelag Health Study (HUNT). JAMA Cardiol. 2018;3(8):721\u20138. https:\/\/doi.org\/10.1001\/jamacardio.2018.1901.","journal-title":"JAMA Cardiol."},{"issue":"3","key":"2086_CR72","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1378\/chest.121.3.846","volume":"121","author":"DH Au","year":"2002","unstructured":"Au DH, Curtis JR, Every NR, et al. Association between inhaled \u03b2-agonists and the risk of unstable angina and myocardial infarction. Chest. 2002;121(3):846\u201351. https:\/\/doi.org\/10.1378\/chest.121.3.846.","journal-title":"Chest"},{"issue":"1","key":"2086_CR73","doi-asserted-by":"publisher","first-page":"17915","DOI":"10.1038\/s41598-017-17890-1","volume":"7","author":"CH Lee","year":"2017","unstructured":"Lee CH, Choi S, Jang EJ, et al. Inhaled bronchodilators and acute myocardial infarction: a nested case\u2013control study. Sci Rep. 2017;7(1):17915. https:\/\/doi.org\/10.1038\/s41598-017-17890-1.","journal-title":"Sci Rep"},{"issue":"6","key":"2086_CR74","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1378\/chest.101.6.1699","volume":"101","author":"ED Robin","year":"1992","unstructured":"Robin ED, McCauley R. Sudden cardiac death in bronchial asthma, and inhaled beta-adrenergic agonists. Chest. 1992;101(6):1699\u2013702. https:\/\/doi.org\/10.1378\/chest.101.6.1699.","journal-title":"Chest"},{"issue":"7","key":"2086_CR75","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1097\/HJH.0b013e32832c4e06","volume":"27","author":"I Squire","year":"2009","unstructured":"Squire I. Shortness of breath, prescription of bronchodilators and the risk of myocardial infarction. J Hypertens. 2009;27(7):1358\u20139. https:\/\/doi.org\/10.1097\/HJH.0b013e32832c4e06.","journal-title":"J Hypertens"},{"issue":"5","key":"2086_CR76","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1046\/j.1365-2796.1998.00291.x","volume":"243","author":"J Rossinen","year":"1998","unstructured":"Rossinen J, Partanen J, Stenius-Aarniala B, et al. Salbutamol inhalation has no effect on myocardial ischaemia, arrhythmias and heart-rate variability in patients with coronary artery disease plus asthma or chronic obstructive pulmonary disease. J Intern Med. 1998;243(5):361\u20136. https:\/\/doi.org\/10.1046\/j.1365-2796.1998.00291.x.","journal-title":"J Intern Med"},{"issue":"Suppl 1","key":"2086_CR77","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/pds.3860","volume":"25","author":"MJ Uddin","year":"2016","unstructured":"Uddin MJ, Groenwold RH, de Boer A, et al. Evaluating different physician\u2019s prescribing preference based instrumental variables in two primary care databases: a study of inhaled long-acting beta2-agonist use and the risk of myocardial infarction. Pharmacoepidemiol Drug Saf. 2016;25(Suppl 1):132\u201341. https:\/\/doi.org\/10.1002\/pds.3860.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"2086_CR78","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.ahj.2004.03.048","volume":"148","author":"DH Au","year":"2004","unstructured":"Au DH, Udris EM, Curtis JR, et al. Association between chronic heart failure and inhaled \u03b2-2-adrenoceptor agonists. Am Heart J. 2004;148(5):915\u201320. https:\/\/doi.org\/10.1016\/j.ahj.2004.03.048.","journal-title":"Am Heart J"},{"issue":"5","key":"2086_CR79","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1536\/ihj.20-825","volume":"62","author":"Z Li","year":"2021","unstructured":"Li Z, Ling Y, Chen Q, et al. Inhaled beta2-agonists increase in-hospital mortality in ICU patients with heart failure. Int Heart J. 2021;62(5):1076\u201382. https:\/\/doi.org\/10.1536\/ihj.20-825.","journal-title":"Int Heart J"},{"issue":"4","key":"2086_CR80","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1054\/jcaf.2002.127771","volume":"8","author":"DM Sengstock","year":"2002","unstructured":"Sengstock DM, Obeidat O, Pasnoori V, et al. Asthma, \u03b2-agonists, and development of congestive heart failure: results of the ABCHF study. J Card Fail. 2002;8(4):232\u20138. https:\/\/doi.org\/10.1054\/jcaf.2002.127771.","journal-title":"J Card Fail"},{"issue":"8","key":"2086_CR81","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1093\/eurjhf\/hfr063","volume":"13","author":"M Bermingham","year":"2011","unstructured":"Bermingham M, O\u2019Callaghan E, Dawkins I, et al. Are beta2-agonists responsible for increased mortality in heart failure? Eur J Heart Fail. 2011;13(8):885\u201391. https:\/\/doi.org\/10.1093\/eurjhf\/hfr063.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"2086_CR82","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jemermed.2007.11.056","volume":"40","author":"CA Maak","year":"2011","unstructured":"Maak CA, Tabas JA, McClintock DE. Should acute treatment with inhaled beta agonists be withheld from patients with dyspnea who may have heart failure? J Emerg Med. 2011;40(2):135\u201345. https:\/\/doi.org\/10.1016\/j.jemermed.2007.11.056.","journal-title":"J Emerg Med"},{"issue":"3","key":"2086_CR83","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.hrtlng.2012.11.007","volume":"42","author":"AG Minasian","year":"2013","unstructured":"Minasian AG, van den Elshout FJ, Dekhuijzen PN, et al. Bronchodilator responsiveness in patients with chronic heart failure. Heart Lung. 2013;42(3):208\u201314. https:\/\/doi.org\/10.1016\/j.hrtlng.2012.11.007.","journal-title":"Heart Lung"},{"issue":"7","key":"2086_CR84","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1136\/thorax.56.7.567","volume":"56","author":"J Burggraaf","year":"2001","unstructured":"Burggraaf J, Westendorp RG, in\u2019t Veen JC, et al. Cardiovascular side effects of inhaled salbutamol in hypoxic asthmatic patients. Thorax. 2001;56(7):567\u20139. https:\/\/doi.org\/10.1136\/thorax.56.7.567.","journal-title":"Thorax"},{"key":"2086_CR85","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.2147\/COPD.S35892","volume":"17","author":"JE Amegadzie","year":"2022","unstructured":"Amegadzie JE, Gamble JM, Farrell J, et al. Association between inhaled \u03b2-agonists initiation and risk of major adverse cardiovascular events: a population-based nested case\u2013control study. Int J Chron Obstruct Pulmon Dis. 2022;17:1205\u201317. https:\/\/doi.org\/10.2147\/COPD.S35892.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2086_CR86","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1183\/2312508X.10028619","volume-title":"Cardiovascular complications of respiratory disorders (ERS Monograph)","author":"D Stolz","year":"2020","unstructured":"Stolz D, Cazzola M. Characterising the cardiovascular safety profile of inhaled muscarinic receptor antagonists. In: Mart\u00ednez-Garc\u00eda MA, P\u00e9pin J-L, Cazzola M, editors. Cardiovascular complications of respiratory disorders (ERS Monograph). Sheffield: European Respiratory Society; 2020. p. 238\u201350. https:\/\/doi.org\/10.1183\/2312508X.10028619."},{"key":"2086_CR87","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/164_2016_68","volume":"237","author":"MG Matera","year":"2017","unstructured":"Matera MG, Cazzola M. Muscarinic receptor antagonists. Handb Exp Pharmacol. 2017;237:41\u201362. https:\/\/doi.org\/10.1007\/164_2016_68.","journal-title":"Handb Exp Pharmacol"},{"issue":"2","key":"2086_CR88","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.ijcard.2014.09.178","volume":"177","author":"S Patan\u00e8","year":"2014","unstructured":"Patan\u00e8 S. M3 muscarinic acetylcholine receptor in cardiology and oncology. Int J Cardiol. 2014;177(2):646\u20139. https:\/\/doi.org\/10.1016\/j.ijcard.2014.09.178.","journal-title":"Int J Cardiol"},{"issue":"3","key":"2086_CR89","doi-asserted-by":"publisher","first-page":"372","DOI":"10.2174\/138945013804998963","volume":"14","author":"P Hang","year":"2013","unstructured":"Hang P, Zhao J, Qi J, et al. Novel insights into the pervasive role of M3 muscarinic receptor in cardiac diseases. Curr Drug Targets. 2013;14(3):372\u20137. https:\/\/doi.org\/10.2174\/138945013804998963.","journal-title":"Curr Drug Targets"},{"issue":"1","key":"2086_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1152\/physiolgenomics.00062.2017","volume":"50","author":"HC Saternos","year":"2018","unstructured":"Saternos HC, Almarghalani DA, Gibson HM, et al. Distribution and function of the muscarinic receptor subtypes in the cardiovascular system. Physiol Genomics. 2018;50(1):1\u20139. https:\/\/doi.org\/10.1152\/physiolgenomics.00062.2017.","journal-title":"Physiol Genomics"},{"issue":"3","key":"2086_CR91","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1124\/pr.111.004580","volume":"64","author":"M Cazzola","year":"2012","unstructured":"Cazzola M, Page CP, Calzetta L, et al. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012;64(3):450\u2013504. https:\/\/doi.org\/10.1124\/pr.111.004580.","journal-title":"Pharmacol Rev"},{"issue":"6","key":"2086_CR92","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1378\/chest.105.6.1701","volume":"105","author":"PM Lehrer","year":"1994","unstructured":"Lehrer PM, Hochron SM, Rausch L, et al. Effects of aerosol ipratropium bromide on cardiac vagal tone. Chest. 1994;105(6):1701\u20134. https:\/\/doi.org\/10.1378\/chest.105.6.1701.","journal-title":"Chest"},{"issue":"4","key":"2086_CR93","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/phar.1336","volume":"34","author":"S Adimadhyam","year":"2014","unstructured":"Adimadhyam S, Schumock GT, Walton S, et al. Risk of arrhythmias associated with ipratropium bromide in children, adolescents, and young adults with asthma: a nested case\u2013control study. Pharmacotherapy. 2014;34(4):315\u201323. https:\/\/doi.org\/10.1002\/phar.1336.","journal-title":"Pharmacotherapy"},{"issue":"13","key":"2086_CR94","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1208606","volume":"367","author":"HA Kerstjens","year":"2012","unstructured":"Kerstjens HA, Engel M, Dahl R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012;367(13):1198\u2013207. https:\/\/doi.org\/10.1056\/NEJMoa1208606.","journal-title":"N Engl J Med"},{"issue":"5","key":"2086_CR95","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S2213-2600(15)00031-4","volume":"3","author":"HA Kerstjens","year":"2015","unstructured":"Kerstjens HA, Casale TB, Bleecker ER, et al. Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials. Lancet Respir Med. 2015;3(5):367\u201376. https:\/\/doi.org\/10.1016\/S2213-2600(15)00031-4.","journal-title":"Lancet Respir Med"},{"issue":"4","key":"2086_CR96","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0124109","volume":"10","author":"K Ohta","year":"2015","unstructured":"Ohta K, Ichinose M, Tohda Y, et al. Long-term once-daily tiotropium Respimat\u00ae is well tolerated and maintains efficacy over 52 weeks in patients with symptomatic asthma in Japan: a randomised, placebo-controlled study. PLoS ONE. 2015;10(4): e0124109. https:\/\/doi.org\/10.1371\/journal.pone.0124109.","journal-title":"PLoS ONE"},{"key":"2086_CR97","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-024-00677-3","author":"MG Matera","year":"2024","unstructured":"Matera MG, Calzetta L, Rogliani P, et al. Cardiovascular events with the use of long-acting muscarinic receptor antagonists: an analysis of the FAERS database 2020\u20132023. Lung. 2024. https:\/\/doi.org\/10.1007\/s00408-024-00677-3.","journal-title":"Lung"},{"key":"2086_CR98","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ebiom.2017.04.020","volume":"19","author":"X Li","year":"2017","unstructured":"Li X, Obeidat M, Zhou G, et al. Responsiveness to ipratropium bromide in male and female patients with mild to moderate chronic obstructive pulmonary disease. EBioMedicine. 2017;19:139\u201345. https:\/\/doi.org\/10.1016\/j.ebiom.2017.04.020.","journal-title":"EBioMedicine"},{"key":"2086_CR99","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ebiom.2017.04.035","volume":"19","author":"L Calzetta","year":"2017","unstructured":"Calzetta L, Puxeddu E, Rogliani P. Gender-related responsiveness to the pharmacological treatment of COPD: a first step towards the personalized medicine. EBioMedicine. 2017;19:14\u20135. https:\/\/doi.org\/10.1016\/j.ebiom.2017.04.035.","journal-title":"EBioMedicine"},{"key":"2086_CR100","doi-asserted-by":"publisher","first-page":"565","DOI":"10.2147\/JAA.S283489","volume":"15","author":"P Rogliani","year":"2022","unstructured":"Rogliani P, Cavalli F, Chetta A, et al. Potential drawbacks of ICS\/LABA\/LAMA triple fixed-dose combination therapy in the treatment of asthma: a quantitative synthesis of safety profile. J Asthma Allergy. 2022;15:565\u201377. https:\/\/doi.org\/10.2147\/JAA.S283489.","journal-title":"J Asthma Allergy."},{"issue":"6","key":"2086_CR101","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1378\/chest.99.6.1415","volume":"99","author":"G Bittar","year":"1991","unstructured":"Bittar G, Friedman HS. The arrhythmogenicity of theophylline. A multivariate analysis of clinical determinants. Chest. 1991;99(6):1415\u201320. https:\/\/doi.org\/10.1378\/chest.99.6.1415.","journal-title":"Chest"},{"key":"2086_CR102","doi-asserted-by":"publisher","DOI":"10.1002\/adtp.202400103","author":"M Cazzola","year":"2024","unstructured":"Cazzola M, Page CP, Calzetta L, Rogliani P, Matera MG. Doxofylline: advancing and empowering equitable asthma and COPD management beyond tradition. Adv Ther. 2024. https:\/\/doi.org\/10.1002\/adtp.202400103.","journal-title":"Adv Ther"},{"key":"2086_CR103","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.pupt.2018.09.007","volume":"53","author":"L Calzetta","year":"2018","unstructured":"Calzetta L, Hanania NA, Dini FL, et al. Impact of doxofylline compared to theophylline in asthma: a pooled analysis of functional and clinical outcomes from two multicentre, double-blind, randomized studies (DOROTHEO 1 and DOROTHEO 2). Pulm Pharmacol Ther. 2018;53:20\u20136. https:\/\/doi.org\/10.1016\/j.pupt.2018.09.007.","journal-title":"Pulm Pharmacol Ther"},{"issue":"1","key":"2086_CR104","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10557-008-6140-9","volume":"23","author":"M B\u00e4ck","year":"2009","unstructured":"B\u00e4ck M. Leukotriene signaling in atherosclerosis and ischemia. Cardiovasc Drugs Ther. 2009;23(1):41\u20138. https:\/\/doi.org\/10.1007\/s10557-008-6140-9.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"2","key":"2086_CR105","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/med.21251","volume":"33","author":"V Capra","year":"2013","unstructured":"Capra V, B\u00e4ck M, Barbieri SS, et al. Eicosanoids and their drugs in cardiovascular diseases: focus on atherosclerosis and stroke. Med Res Rev. 2013;33(2):364\u2013438. https:\/\/doi.org\/10.1002\/med.21251.","journal-title":"Med Res Rev"},{"issue":"10","key":"2086_CR106","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s00109-012-0904-1","volume":"90","author":"A Eaton","year":"2012","unstructured":"Eaton A, Nagy E, Pacault M, et al. Cysteinyl leukotriene signaling through perinuclear CysLT1 receptors on vascular smooth muscle cells transduces nuclear calcium signaling and alterations of gene expression. J Mol Med (Berl). 2012;90(10):1223\u201331. https:\/\/doi.org\/10.1007\/s00109-012-0904-1.","journal-title":"J Mol Med (Berl)"},{"issue":"1","key":"2086_CR107","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1038\/s41598-024-53936-x","volume":"14","author":"M Muluhie","year":"2024","unstructured":"Muluhie M, Castiglioni L, Rzemieniec J, et al. Montelukast, an available and safe anti-asthmatic drug, prevents maladaptive remodelling and maintains cardiac functionality following myocardial infarction. Sci Rep. 2024;14(1):3371. https:\/\/doi.org\/10.1038\/s41598-024-53936-x.","journal-title":"Sci Rep"},{"key":"2086_CR108","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.biopha.2018.12.064","volume":"111","author":"X Zhou","year":"2019","unstructured":"Zhou X, Cai J, Liu W, et al. Cysteinyl leukotriene receptor type 1 (CysLT1R) antagonist zafirlukast protects against TNF-\u03b1-induced endothelial inflammation. Biomed Pharmacother. 2019;111:452\u20139. https:\/\/doi.org\/10.1016\/j.biopha.2018.12.064.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"2086_CR109","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.jaci.2011.11.052","volume":"129","author":"E Ingelsson","year":"2012","unstructured":"Ingelsson E, Yin L, B\u00e4ck M. Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease. J Allergy Clin Immunol. 2012;129(3):702-707.e2. https:\/\/doi.org\/10.1016\/j.jaci.2011.11.052.","journal-title":"J Allergy Clin Immunol"},{"key":"2086_CR110","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.611561","volume":"11","author":"M Hoxha","year":"2021","unstructured":"Hoxha M, Tedesco CC, Quaglin S, et al. Montelukast use decreases cardiovascular events in asthmatics. Front Pharmacol. 2021;11: 611561. https:\/\/doi.org\/10.3389\/fphar.2020.611561.","journal-title":"Front Pharmacol"},{"issue":"3","key":"2086_CR111","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1378\/chest.07-0831","volume":"132","author":"H Allayee","year":"2007","unstructured":"Allayee H, Hartiala J, Lee W, et al. The effect of montelukast and low-dose theophylline on cardiovascular disease risk factors in asthmatics. Chest. 2007;132(3):868\u201374. https:\/\/doi.org\/10.1378\/chest.07-0831.","journal-title":"Chest"},{"issue":"8","key":"2086_CR112","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1111\/jgs.14235","volume":"64","author":"SM Altawalbeh","year":"2016","unstructured":"Altawalbeh SM, Thorpe CT, Zgibor JC, et al. Antileukotriene agents versus long-acting beta-agonists in older adults with persistent asthma: a comparison of add-on therapies. J Am Geriatr Soc. 2016;64(8):1592\u2013600. https:\/\/doi.org\/10.1111\/jgs.14235.","journal-title":"J Am Geriatr Soc"},{"key":"2086_CR113","doi-asserted-by":"publisher","first-page":"2102730","DOI":"10.1183\/13993003.02730-2021","volume":"59","author":"HK Reddel","year":"2022","unstructured":"Reddel HK, Bacharier LB, Bateman ED, et al. Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes. Eur Respir J. 2022;59:2102730. https:\/\/doi.org\/10.1183\/13993003.02730-2021.","journal-title":"Eur Respir J"},{"issue":"20","key":"2086_CR114","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1056\/NEJMoa1003833","volume":"366","author":"WA Ray","year":"2012","unstructured":"Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012;366(20):1881\u201390. https:\/\/doi.org\/10.1056\/NEJMoa1003833.","journal-title":"N Engl J Med"},{"issue":"10","key":"2086_CR115","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1164\/rccm.201402-0385CI","volume":"189","author":"RK Albert","year":"2014","unstructured":"Albert RK, Schuller JL, COPD Clinical Research Network. Macrolide antibiotics and the risk of cardiac arrhythmias. Am J Respir Crit Care Med. 2014;189(10):1173\u201380. https:\/\/doi.org\/10.1164\/rccm.201402-0385CI.","journal-title":"Am J Respir Crit Care Med"},{"key":"2086_CR116","unstructured":"Food and Drug Administration. FDA Drug Safety Communication: azithromycin (Zithromax or Zmax) and the risk of potentially fatal heart rhythms. 2013. http:\/\/www.fda.gov\/drugs\/drugsafety\/ucm341822.htm. Accessed 30 Mar 2024."},{"issue":"1","key":"2086_CR117","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2019-000489","volume":"7","author":"D Smith","year":"2020","unstructured":"Smith D, Du Rand IA, Addy C, et al. British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease. BMJ Open Respir Res. 2020;7(1): e000489. https:\/\/doi.org\/10.1136\/bmjresp-2019-000489.","journal-title":"BMJ Open Respir Res"},{"key":"2086_CR118","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.atherosclerosis.2016.05.045","volume":"251","author":"NG Kounis","year":"2016","unstructured":"Kounis NG, Hahalis G. Serum IgE levels in coronary artery disease. Atherosclerosis. 2016;251:498\u2013500. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.05.045.","journal-title":"Atherosclerosis"},{"issue":"5","key":"2086_CR119","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.jaci.2016.07.038","volume":"139","author":"C Iribarren","year":"2017","unstructured":"Iribarren C, Rahmaoui A, Long AA, et al. Cardiovascular and cerebrovascular events among patients receiving omalizumab: results from EXCELS, a prospective cohort study in moderate to severe asthma. J Allergy Clin Immunol. 2017;139(5):1489\u201395. https:\/\/doi.org\/10.1016\/j.jaci.2016.07.038.","journal-title":"J Allergy Clin Immunol"},{"key":"2086_CR120","doi-asserted-by":"publisher","first-page":"117739281986198","DOI":"10.1177\/1177392819861987","volume":"13","author":"CM Oblitas","year":"2019","unstructured":"Oblitas CM, Galeano-Valle F, Vela-De La Cruz L, et al. Omalizumab as a provoking factor for venous thromboembolism. Drug Target Insights. 2019;13:1177392819861987. https:\/\/doi.org\/10.1177\/1177392819861987.","journal-title":"Drug Target Insights."},{"issue":"3","key":"2086_CR121","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1016\/j.jaip.2020.12.031","volume":"9","author":"JB Quinta","year":"2021","unstructured":"Quinta JB, Montastruc F, Sommet A, et al. Cardiovascular adverse effects of anti-IL-5\/IL-5R\u03b1 therapies: a real-world study. J Allergy Clin Immunol Pract. 2021;9(3):1411\u20133. https:\/\/doi.org\/10.1016\/j.jaip.2020.12.031.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"2086_CR122","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1016\/j.jaci.2016.12.953","volume":"139","author":"C Iribarren","year":"2017","unstructured":"Iribarren C, Rothman KJ, Bradley MS, et al. Cardiovascular and cerebrovascular events among patients receiving omalizumab: pooled analysis of patient-level data from 25 randomized, double-blind, placebo-controlled clinical trials. J Allergy Clin Immunol. 2017;139(5):1678\u201380. https:\/\/doi.org\/10.1016\/j.jaci.2016.12.953.","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"2086_CR123","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2022.100726","volume":"15","author":"ER Bleecker","year":"2022","unstructured":"Bleecker ER, Al-Ahmad M, Bjermer L, et al. Systemic corticosteroids in asthma: a call to action from World Allergy Organization and Respiratory Effectiveness Group. World Allergy Organ J. 2022;15(12): 100726. https:\/\/doi.org\/10.1016\/j.waojou.2022.100726.","journal-title":"World Allergy Organ J"},{"key":"2086_CR124","doi-asserted-by":"publisher","first-page":"9355606","DOI":"10.1155\/2022\/9355606","volume":"2022","author":"DR Dorscheid","year":"2022","unstructured":"Dorscheid DR, Lee JK, Ramesh W, et al. Guidance for administering biologics for severe asthma and allergic conditions. Can Respir J. 2022;2022:9355606. https:\/\/doi.org\/10.1155\/2022\/9355606.","journal-title":"Can Respir J"},{"issue":"2","key":"2086_CR125","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.resinv.2022.12.004","volume":"61","author":"P Alton","year":"2023","unstructured":"Alton P, Hughes DM, Zhao SS. Cardiovascular safety of genetically proxied interleukin-5 inhibition: a Mendelian randomization study. Respir Investig. 2023;61(2):149\u201352. https:\/\/doi.org\/10.1016\/j.resinv.2022.12.004.","journal-title":"Respir Investig"},{"issue":"8","key":"2086_CR126","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.jacbts.2019.07.002","volume":"4","author":"A Knutsson","year":"2019","unstructured":"Knutsson A, Bj\u00f6rkbacka H, Dun\u00e9r P, et al. Associations of interleukin-5 with plaque development and cardiovascular events. JACC Basic Transl Sci. 2019;4(8):891\u2013902. https:\/\/doi.org\/10.1016\/j.jacbts.2019.07.002.","journal-title":"JACC Basic Transl Sci."},{"issue":"6","key":"2086_CR127","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.3390\/cells10061392","volume":"10","author":"HA Kader","year":"2021","unstructured":"Kader HA, Azeem M, Jwayed SA, et al. Current insights into immunology and novel therapeutics of atopic dermatitis. Cells. 2021;10(6):1392. https:\/\/doi.org\/10.3390\/cells10061392.","journal-title":"Cells"},{"issue":"3","key":"2086_CR128","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1067\/mai.2001.113237","volume":"107","author":"T Kakinuma","year":"2001","unstructured":"Kakinuma T, Nakamura K, Wakugawa M, et al. Thymus and activation-regulated chemokine in atopic dermatitis: serum thymus and activation-regulated chemokine level is closely related with disease activity. J Allergy Clin Immunol. 2001;107(3):535\u201341. https:\/\/doi.org\/10.1067\/mai.2001.113237.","journal-title":"J Allergy Clin Immunol"},{"key":"2086_CR129","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s44161-023-00413-9","volume":"3","author":"Y D\u00f6ring","year":"2024","unstructured":"D\u00f6ring Y, van der Vorst EPC, Yan Y, et al. Identification of a non-canonical chemokine-receptor pathway suppressing regulatory T cells to drive atherosclerosis. Nat Cardiovasc Res. 2024;3:221\u201342. https:\/\/doi.org\/10.1038\/s44161-023-00413-9.","journal-title":"Nat Cardiovasc Res."},{"issue":"3","key":"2086_CR130","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/1346-8138.12440","volume":"41","author":"Y Kataoka","year":"2014","unstructured":"Kataoka Y. Thymus and activation-regulated chemokine as a clinical biomarker in atopic dermatitis. J Dermatol. 2014;41(3):221\u20139. https:\/\/doi.org\/10.1111\/1346-8138.12440.","journal-title":"J Dermatol"},{"issue":"10","key":"2086_CR131","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1111\/all.14859","volume":"76","author":"AP Villani","year":"2021","unstructured":"Villani AP, Pavel AB, Wu J, et al. Vascular inflammation in moderate-to-severe atopic dermatitis is associated with enhanced Th2 response. Allergy. 2021;76(10):3107\u201321. https:\/\/doi.org\/10.1111\/all.14859.","journal-title":"Allergy"},{"key":"2086_CR132","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.3389\/fimmu.2020.01768","volume":"11","author":"H He","year":"2020","unstructured":"He H, Olesen CM, Pavel AB, et al. Tape-strip proteomic profiling of atopic dermatitis on dupilumab identifies minimally invasive biomarkers. Front Immunol. 2020;11:1768. https:\/\/doi.org\/10.3389\/fimmu.2020.01768.","journal-title":"Front Immunol"},{"issue":"3","key":"2086_CR133","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/psb.2050","volume":"34","author":"S Chaplin","year":"2023","unstructured":"Chaplin S. Tezepelumab as add-on treatment for severe asthma. Prescriber. 2023;34(3):13\u20134. https:\/\/doi.org\/10.1002\/psb.2050.","journal-title":"Prescriber"},{"issue":"2","key":"2086_CR134","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40265-024-01995-9","volume":"84","author":"WAM Schonck","year":"2024","unstructured":"Schonck WAM, Stroes ESG, Hovingh GK, Reeskamp LF. Long-term efficacy and tolerability of PCSK9 targeted therapy: a review of the literature. Drugs. 2024;84(2):165\u201378. https:\/\/doi.org\/10.1007\/s40265-024-01995-9.","journal-title":"Drugs"},{"issue":"3","key":"2086_CR135","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1136\/thoraxjnl-2016-208412","volume":"72","author":"JG Baker","year":"2017","unstructured":"Baker JG, Wilcox RG. \u03b2-Blockers, heart disease and COPD: current controversies and uncertainties. Thorax. 2017;72(3):271\u20136. https:\/\/doi.org\/10.1136\/thoraxjnl-2016-208412.","journal-title":"Thorax"},{"issue":"4","key":"2086_CR136","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1378\/chest.13-1235","volume":"145","author":"DR Morales","year":"2014","unstructured":"Morales DR, Jackson C, Lipworth BJ, et al. Adverse respiratory effect of acute \u03b2-blocker exposure in asthma: a systematic review and meta-analysis of randomized controlled trials. Chest. 2014;145(4):779\u201386. https:\/\/doi.org\/10.1378\/chest.13-1235.","journal-title":"Chest"},{"issue":"1","key":"2086_CR137","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12916-017-0781-0","volume":"15","author":"DR Morales","year":"2017","unstructured":"Morales DR, Lipworth BJ, Donnan PT, et al. Respiratory effect of beta-blockers in people with asthma and cardiovascular disease: population-based nested case control study. BMC Med. 2017;15(1):18. https:\/\/doi.org\/10.1186\/s12916-017-0781-0.","journal-title":"BMC Med"},{"issue":"1","key":"2086_CR138","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/bcp.12181","volume":"77","author":"DW Loth","year":"2014","unstructured":"Loth DW, Brusselle GG, Lahousse L, et al. \u03b2-Adrenoceptor blockers and pulmonary function in the general population: the Rotterdam study. Br J Clin Pharmacol. 2014;77(1):190\u2013200. https:\/\/doi.org\/10.1111\/bcp.12181.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"2086_CR139","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/sj.bjp.0706048","volume":"144","author":"JG Baker","year":"2005","unstructured":"Baker JG. The selectivity of \u03b2-adrenoceptor antagonists at the human \u03b21, \u03b22 and \u03b23 adrenoceptors. Br J Pharmacol. 2005;144(3):317\u201322. https:\/\/doi.org\/10.1038\/sj.bjp.0706048.","journal-title":"Br J Pharmacol"},{"key":"2086_CR140","doi-asserted-by":"publisher","first-page":"CD002992","DOI":"10.1002\/14651858.CD002992","volume":"1","author":"S Salpeter","year":"2002","unstructured":"Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for reversible airway disease. Cochrane Database Syst Rev. 2002;1:CD002992. https:\/\/doi.org\/10.1002\/14651858.CD002992.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2086_CR141","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s41598-020-79837-3","volume":"11","author":"KY Huang","year":"2021","unstructured":"Huang KY, Tseng PT, Wu YC, et al. Do beta-adrenergic blocking agents increase asthma exacerbation? A network meta-analysis of randomized controlled trials. Sci Rep. 2021;11(1):452. https:\/\/doi.org\/10.1038\/s41598-020-79837-3.","journal-title":"Sci Rep"},{"issue":"1","key":"2086_CR142","doi-asserted-by":"publisher","first-page":"00801","DOI":"10.1183\/23120541.00801-2020","volume":"7","author":"M Bennett","year":"2021","unstructured":"Bennett M, Chang CL, Tatley M, et al. The safety of cardioselective \u03b21-blockers in asthma: literature review and search of global pharmacovigilance safety reports. ERJ Open Res. 2021;7(1):00801\u20132020. https:\/\/doi.org\/10.1183\/23120541.00801-2020.","journal-title":"ERJ Open Res."},{"issue":"2","key":"2086_CR143","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.coph.2006.10.005","volume":"7","author":"S Parra","year":"2007","unstructured":"Parra S, Bond RA. Inverse agonism: from curiosity to accepted dogma, but is it clinically relevant? Curr Opin Pharmacol. 2007;7(2):146\u201350. https:\/\/doi.org\/10.1016\/j.coph.2006.10.005.","journal-title":"Curr Opin Pharmacol"},{"issue":"1","key":"2086_CR144","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/j.1476-5381.2010.01178.x","volume":"163","author":"JK Walker","year":"2011","unstructured":"Walker JK, Penn RB, Hanania NA, et al. New perspectives regarding \u03b22-adrenoceptor ligands in the treatment of asthma. Br J Pharmacol. 2011;163(1):18\u201328. https:\/\/doi.org\/10.1111\/j.1476-5381.2010.01178.x.","journal-title":"Br J Pharmacol"},{"issue":"18","key":"2086_CR145","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1016\/j.jacc.2015.02.038","volume":"65","author":"C Rosendorff","year":"2015","unstructured":"Rosendorff C, Lackland DT, Allison M, et al. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. J Am Coll Cardiol. 2015;65(18):1998\u20132038. https:\/\/doi.org\/10.1016\/j.jacc.2015.02.038.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2086_CR146","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.pupt.2007.07.002","volume":"21","author":"NA Hanania","year":"2008","unstructured":"Hanania NA, Singh S, El-Wali R, et al. The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study. Pulm Pharmacol Ther. 2008;21(1):134\u201341. https:\/\/doi.org\/10.1016\/j.pupt.2007.07.002.","journal-title":"Pulm Pharmacol Ther"},{"issue":"4","key":"2086_CR147","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1183\/09031936.00003210","volume":"36","author":"NA Hanania","year":"2010","unstructured":"Hanania NA, Mannava B, Franklin AE, et al. Response to salbutamol in patients with mild asthma treated with nadolol. Eur Respir J. 2010;36(4):963\u20135. https:\/\/doi.org\/10.1183\/09031936.00003210.","journal-title":"Eur Respir J"},{"issue":"3","key":"2086_CR148","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/resp.13955","volume":"26","author":"MR Bennett","year":"2021","unstructured":"Bennett MR, Chang CL, Tuffery C, et al. The impact of regular bisoprolol on the response to salbutamol in asthma: a double-blind randomized placebo-controlled crossover trial. Respirology. 2021;26(3):225\u201332. https:\/\/doi.org\/10.1111\/resp.13955.","journal-title":"Respirology"},{"issue":"7","key":"2086_CR149","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1080\/14740338.2024.2362817","volume":"23","author":"MG Matera","year":"2024","unstructured":"Matera MG, Rogliani P, Calzetta L, Cazzola M. An overview of the efficacy and safety of \u03b22-adrenoceptor antagonists for the treatment of chronic obstructive pulmonary disease. Expert Opin Drug Saf. 2024;23(7):833\u201344. https:\/\/doi.org\/10.1080\/14740338.2024.2362817.","journal-title":"Expert Opin Drug Saf"},{"issue":"9","key":"2086_CR150","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1080\/17476348.2019.1649147","volume":"13","author":"A Tiotiu","year":"2019","unstructured":"Tiotiu A, Novakova P, Kowal K, et al. Beta-blockers in asthma: myth and reality. Expert Rev Respir Med. 2019;13(9):815\u201322. https:\/\/doi.org\/10.1080\/17476348.2019.1649147.","journal-title":"Expert Rev Respir Med"},{"key":"2086_CR151","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.pupt.2014.05.007","volume":"30","author":"S Oehme","year":"2015","unstructured":"Oehme S, Mittag A, Schr\u00f6dl W, et al. Agonist-induced \u03b22-adrenoceptor desensitization and downregulation enhance pro-inflammatory cytokine release in human bronchial epithelial cells. Pulm Pharmacol Ther. 2015;30:110\u201320. https:\/\/doi.org\/10.1016\/j.pupt.2014.05.007.","journal-title":"Pulm Pharmacol Ther"},{"issue":"2","key":"2086_CR152","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.pupt.2014.04.005","volume":"28","author":"B Rinaldi","year":"2014","unstructured":"Rinaldi B, Capuano A, Gritti G, et al. Effects of chronic administration of \u03b2-blockers on airway responsiveness in a murine model of heart failure. Pulm Pharmacol Ther. 2014;28(2):109\u201313. https:\/\/doi.org\/10.1016\/j.pupt.2014.04.005.","journal-title":"Pulm Pharmacol Ther"},{"issue":"17","key":"2086_CR153","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJM199210223271703","volume":"327","author":"D Cheung","year":"1992","unstructured":"Cheung D, Timmers MC, Zwinderman AH, et al. Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med. 1992;327(17):1198\u2013203. https:\/\/doi.org\/10.1056\/NEJM199210223271703.","journal-title":"N Engl J Med"},{"issue":"1","key":"2086_CR154","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.pupt.2007.06.003","volume":"21","author":"R Lin","year":"2008","unstructured":"Lin R, Peng H, Nguyen LP, et al. Changes in \u03b22-adrenoceptor and other signaling proteins produced by chronic administration of \u201cbeta-blockers\u201d in a murine asthma model. Pulm Pharmacol Ther. 2008;21(1):115\u201324. https:\/\/doi.org\/10.1016\/j.pupt.2007.06.003.","journal-title":"Pulm Pharmacol Ther"},{"issue":"14","key":"2086_CR155","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1111\/bph.13148","volume":"172","author":"B Rinaldi","year":"2015","unstructured":"Rinaldi B, Donniacuo M, Sodano L, et al. Effects of chronic treatment with the new ultra-long-acting \u03b22-adrenoceptor agonist indacaterol alone or in combination with the \u03b21-adrenoceptor blocker metoprolol on cardiac remodelling. Br J Pharmacol. 2015;172(14):3627\u201337. https:\/\/doi.org\/10.1111\/bph.13148.","journal-title":"Br J Pharmacol"},{"issue":"5","key":"2086_CR156","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s40256-016-0173-3","volume":"16","author":"S Taddei","year":"2016","unstructured":"Taddei S, Bortolotto L. Unraveling the pivotal role of bradykinin in ACE inhibitor activity. Am J Cardiovasc Drugs. 2016;16(5):309\u201321. https:\/\/doi.org\/10.1007\/s40256-016-0173-3.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"11","key":"2086_CR157","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1800345","volume":"381","author":"SC Christiansen","year":"2019","unstructured":"Christiansen SC, Zuraw BL. Treatment of hypertension in patients with asthma. N Engl J Med. 2019;381(11):1046\u201357. https:\/\/doi.org\/10.1056\/NEJMra1800345.","journal-title":"N Engl J Med"},{"issue":"6920","key":"2086_CR158","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/bmj.308.6920.18","volume":"308","author":"H Lunde","year":"1994","unstructured":"Lunde H, Hedner T, Samuelsson O, et al. Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitors. BMJ. 1994;308(6920):18\u201321. https:\/\/doi.org\/10.1136\/bmj.308.6920.18.","journal-title":"BMJ"},{"issue":"1","key":"2086_CR159","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jaip.2015.07.009","volume":"4","author":"SC Christiansen","year":"2016","unstructured":"Christiansen SC, Schatz M, Yang SJ, et al. Hypertension and asthma: a comorbid relationship. J Allergy Clin Immunol Pract. 2016;4(1):76\u201381. https:\/\/doi.org\/10.1016\/j.jaip.2015.07.009.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"9","key":"2086_CR160","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1016\/j.jaip.2021.04.055","volume":"9","author":"DR Morales","year":"2021","unstructured":"Morales DR, Lipworth BJ, Donnan PT, et al. Intolerance to angiotensin converting enzyme inhibitors in asthma and the general population: a UK population-based cohort study. J Allergy Clin Immunol Pract. 2021;9(9):3431\u20139. https:\/\/doi.org\/10.1016\/j.jaip.2021.04.055.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"2086_CR161","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1345\/aph.1A332","volume":"36","author":"KA Packard","year":"2002","unstructured":"Packard KA, Wurdeman RL, Arouni AJ. ACE inhibitor-induced bronchial reactivity in patients with respiratory dysfunction. Ann Pharmacother. 2002;36(6):1058\u201367. https:\/\/doi.org\/10.1345\/aph.1A332.","journal-title":"Ann Pharmacother"},{"issue":"9","key":"2086_CR162","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1016\/j.jaip.2021.07.002","volume":"9","author":"WJ Song","year":"2021","unstructured":"Song WJ, Niimi A. Angiotensin-converting enzyme inhibitors, asthma, and cough: relighting the torch. J Allergy Clin Immunol Pract. 2021;9(9):3440\u20131. https:\/\/doi.org\/10.1016\/j.jaip.2021.07.002.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"2086_CR163","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/BF03261835","volume":"12","author":"D Caldeira","year":"2012","unstructured":"Caldeira D, David C, Sampaio C. Tolerability of angiotensin-receptor blockers in patients with intolerance to angiotensin-converting enzyme inhibitors: a systematic review and meta-analysis. Am J Cardiovasc Drugs. 2012;12(4):263\u201377. https:\/\/doi.org\/10.1007\/BF03261835.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"1","key":"2086_CR164","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1164\/ajrccm.162.1.9907127","volume":"162","author":"S Myou","year":"2000","unstructured":"Myou S, Fujimura M, Kamio Y, et al. Effect of losartan, a type 1 angiotensin II receptor antagonist, on bronchial hyperresponsiveness to methacholine in patients with bronchial asthma. Am J Respir Crit Care Med. 2000;162(1):40\u20134. https:\/\/doi.org\/10.1164\/ajrccm.162.1.9907127.","journal-title":"Am J Respir Crit Care Med"},{"key":"2086_CR165","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coph.2017.12.002","volume":"40","author":"WSD Tan","year":"2018","unstructured":"Tan WSD, Liao W, Zhou S, et al. Targeting the renin-angiotensin system as novel therapeutic strategy for pulmonary diseases. Curr Opin Pharmacol. 2018;40:9\u201317. https:\/\/doi.org\/10.1016\/j.coph.2017.12.002.","journal-title":"Curr Opin Pharmacol"},{"issue":"1","key":"2086_CR166","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1152\/physrev.00023.2016","volume":"98","author":"RAS Santos","year":"2018","unstructured":"Santos RAS, Sampaio WO, Alzamora AC, et al. The ACE2\/angiotensin-(1\u20137)\/MAS axis of the renin-angiotensin system: focus on angiotensin-(1\u20137). Physiol Rev. 2018;98(1):505\u201353. https:\/\/doi.org\/10.1152\/physrev.00023.2016.","journal-title":"Physiol Rev"},{"issue":"3","key":"2086_CR167","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.coph.2012.04.001","volume":"12","author":"MG Matera","year":"2012","unstructured":"Matera MG, Calzetta L, Rinaldi B, et al. Treatment of COPD: moving beyond the lungs. Curr Opin Pharmacol. 2012;12(3):315\u201322. https:\/\/doi.org\/10.1016\/j.coph.2012.04.001.","journal-title":"Curr Opin Pharmacol"},{"key":"2086_CR168","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.557962","volume":"12","author":"GS Magalh\u00e3es","year":"2021","unstructured":"Magalh\u00e3es GS, Greg\u00f3rio JF, Can\u00e7ado Ribeiro ATP, et al. Oral formulation of angiotensin-(1\u20137) promotes therapeutic actions in a model of eosinophilic and neutrophilic asthma. Front Pharmacol. 2021;12: 557962. https:\/\/doi.org\/10.3389\/fphar.2021.557962.","journal-title":"Front Pharmacol"},{"issue":"22","key":"2086_CR169","doi-asserted-by":"publisher","first-page":"4428","DOI":"10.1111\/bph.15619","volume":"178","author":"JF Greg\u00f3rio","year":"2021","unstructured":"Greg\u00f3rio JF, Rodrigues-Machado MDG, Santos RAS, et al. Asthma: role of the angiotensin-(1\u20137)\/Mas (MAS1) pathway in pathophysiology and therapy. Br J Pharmacol. 2021;178(22):4428\u201339. https:\/\/doi.org\/10.1111\/bph.15619.","journal-title":"Br J Pharmacol"},{"key":"2086_CR170","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.941944","volume":"9","author":"Q Hui","year":"2022","unstructured":"Hui Q, Hao Y, Ye F, et al. Genetically high angiotensin-converting enzyme concentrations causally increase asthma risk: a meta-analysis using Mendelian randomization. Front Med (Lausanne). 2022;9: 941944. https:\/\/doi.org\/10.3389\/fmed.2022.941944.","journal-title":"Front Med (Lausanne)."},{"issue":"3","key":"2086_CR171","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20211001","volume":"219","author":"G Liu","year":"2022","unstructured":"Liu G, Chen Y, Wang Y, et al. Angiotensin II enhances group 2 innate lymphoid cell responses via AT1a during airway inflammation. J Exp Med. 2022;219(3): e20211001. https:\/\/doi.org\/10.1084\/jem.20211001.","journal-title":"J Exp Med"},{"issue":"11","key":"2086_CR172","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1183\/09031936.95.08111838","volume":"8","author":"EA Millar","year":"1995","unstructured":"Millar EA, Nally JE, Thomson NC. Angiotensin II potentiates methacholine-induced bronchoconstriction in human airway both in vitro and in vivo. Eur Respir J. 1995;8(11):1838\u201341. https:\/\/doi.org\/10.1183\/09031936.95.08111838.","journal-title":"Eur Respir J"},{"issue":"3","key":"2086_CR173","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s00424-010-0844-y","volume":"460","author":"H Sakai","year":"2010","unstructured":"Sakai H, Nishizawa Y, Nishimura A, et al. Angiotensin II induces hyperresponsiveness of bronchial smooth muscle via an activation of p42\/44 ERK in rats. Pflugers Arch. 2010;460(3):645\u201355. https:\/\/doi.org\/10.1007\/s00424-010-0844-y.","journal-title":"Pflugers Arch"},{"issue":"4","key":"2086_CR174","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3892\/ijmm.2012.1080","volume":"30","author":"N Li","year":"2012","unstructured":"Li N, Cai R, Niu Y, et al. Inhibition of angiotensin II-induced contraction of human airway smooth muscle cells by angiotensin-(1\u20137) via downregulation of the RhoA\/ROCK2 signaling pathway. Int J Mol Med. 2012;30(4):811\u20138. https:\/\/doi.org\/10.3892\/ijmm.2012.1080.","journal-title":"Int J Mol Med"},{"issue":"19","key":"2086_CR175","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1001\/jama.2016.15450","volume":"316","author":"K Bibbins-Domingo","year":"2016","unstructured":"US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, et al. Statin use for the primary prevention of cardiovascular disease in adults: US preventive services task force recommendation statement. JAMA. 2016;316(19):1997\u20132007. https:\/\/doi.org\/10.1001\/jama.2016.15450.","journal-title":"JAMA"},{"key":"2086_CR176","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2022.102168","volume":"77","author":"D Andreikos","year":"2022","unstructured":"Andreikos D, Karampitsakos T, Tzouvelekis A, et al. Statins\u2019 still controversial role in pulmonary fibrosis: what does the evidence show? Pulm Pharmacol Ther. 2022;77: 102168. https:\/\/doi.org\/10.1016\/j.pupt.2022.102168.","journal-title":"Pulm Pharmacol Ther"},{"issue":"1","key":"2086_CR177","doi-asserted-by":"publisher","first-page":"2300291","DOI":"10.1183\/13993003.00291-2023","volume":"62","author":"HJ Jang","year":"2023","unstructured":"Jang HJ, Lee DY, Loloci G, et al. Association between the use of statins and risk of interstitial lung disease\/idiopathic pulmonary fibrosis: time-dependent analysis of population-based nationwide data. Eur Respir J. 2023;62(1):2300291. https:\/\/doi.org\/10.1183\/13993003.00291-2023.","journal-title":"Eur Respir J"},{"issue":"6","key":"2086_CR178","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1080\/17476348.2018.1457437","volume":"12","author":"AA Zeki","year":"2018","unstructured":"Zeki AA, Elbadawi-Sidhu M. Innovations in asthma therapy: is there a role for inhaled statins? Expert Rev Respir Med. 2018;12(6):461\u201373. https:\/\/doi.org\/10.1080\/17476348.2018.1457437.","journal-title":"Expert Rev Respir Med"},{"issue":"7","key":"2086_CR179","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s40265-017-0731-3","volume":"77","author":"M Cazzola","year":"2017","unstructured":"Cazzola M, Calzetta L, Rinaldi B, et al. Management of chronic obstructive pulmonary disease in patients with cardiovascular diseases. Drugs. 2017;77(7):721\u201332. https:\/\/doi.org\/10.1007\/s40265-017-0731-3.","journal-title":"Drugs"},{"issue":"7","key":"2086_CR180","doi-asserted-by":"publisher","first-page":"CD013268","DOI":"10.1002\/14651858.CD013268.pub2","volume":"7","author":"C Naing","year":"2020","unstructured":"Naing C, Ni H. Statins for asthma. Cochrane Database Syst Rev. 2020;7(7):CD013268. https:\/\/doi.org\/10.1002\/14651858.CD013268.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"2086_CR181","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1016\/j.jaip.2021.04.014","volume":"9","author":"JH Kim","year":"2021","unstructured":"Kim JH, Wee JH, Choi HG, et al. Association between statin medication and asthma\/asthma exacerbation in a national health screening cohort. J Allergy Clin Immunol Pract. 2021;9(7):2783\u201391. https:\/\/doi.org\/10.1016\/j.jaip.2021.04.014.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"2086_CR182","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jaip.2023.10.029","volume":"12","author":"C Park","year":"2024","unstructured":"Park C, Jang JH, Kim C, et al. Real-world effectiveness of statin therapy in adult asthma. J Allergy Clin Immunol Pract. 2024;12(2):399\u2013408. https:\/\/doi.org\/10.1016\/j.jaip.2023.10.029.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"2086_CR183","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1080\/02770903.2021.1879850","volume":"59","author":"K Sunata","year":"2022","unstructured":"Sunata K, Kabata H, Kuno T, et al. The effect of statins for asthma. A systematic review and meta-analysis. J Asthma. 2022;59(4):801\u201310. https:\/\/doi.org\/10.1080\/02770903.2021.1879850.","journal-title":"J Asthma"},{"issue":"22","key":"2086_CR184","doi-asserted-by":"publisher","first-page":"8401","DOI":"10.26355\/eurrev_202211_30376","volume":"26","author":"QX Zhang","year":"2022","unstructured":"Zhang QX, Zhang HF, Lu XT, et al. Statins improve asthma symptoms by suppressing inflammation: a meta-analysis based on RCTs. Eur Rev Med Pharmacol Sci. 2022;26(22):8401\u201310. https:\/\/doi.org\/10.26355\/eurrev_202211_30376.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2086_CR185","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pupt.2015.01.001","volume":"31","author":"NC Thomson","year":"2015","unstructured":"Thomson NC, Charron CE, Chaudhuri R, et al. Atorvastatin in combination with inhaled beclometasone modulates inflammatory sputum mediators in smokers with asthma. Pulm Pharmacol Ther. 2015;31:1\u20138. https:\/\/doi.org\/10.1016\/j.pupt.2015.01.001.","journal-title":"Pulm Pharmacol Ther"},{"issue":"4","key":"2086_CR186","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.jaci.2010.08.005","volume":"126","author":"K Maneechotesuwan","year":"2010","unstructured":"Maneechotesuwan K, Ekjiratrakul W, Kasetsinsombat K, et al. Statins enhance the anti-inflammatory effects of inhaled corticosteroids in asthmatic patients through increased induction of indoleamine 2, 3-dioxygenase. J Allergy Clin Immunol. 2010;126(4):754\u201362. https:\/\/doi.org\/10.1016\/j.jaci.2010.08.005.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"2086_CR187","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/cea.12067","volume":"43","author":"K Maneechotesuwan","year":"2013","unstructured":"Maneechotesuwan K, Kasetsinsombat K, Wamanuttajinda V, et al. Statins enhance the effects of corticosteroids on the balance between regulatory T cells and Th17 cells. Clin Exp Allergy. 2013;43(2):212\u201322. https:\/\/doi.org\/10.1111\/cea.12067.","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"2086_CR188","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/14740338.2018.1394455","volume":"17","author":"S Bellosta","year":"2018","unstructured":"Bellosta S, Corsini A. Statin drug interactions and related adverse reactions: an update. Expert Opin Drug Saf. 2018;17(1):25\u201337. https:\/\/doi.org\/10.1080\/14740338.2018.1394455.","journal-title":"Expert Opin Drug Saf"},{"issue":"10","key":"2086_CR189","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11910-020-01064-0","volume":"20","author":"E Crisan","year":"2020","unstructured":"Crisan E, Patil VK. Neuromuscular complications of statin therapy. Curr Neurol Neurosci Rep. 2020;20(10):47. https:\/\/doi.org\/10.1007\/s11910-020-01064-0.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"1","key":"2086_CR190","first-page":"23","volume":"57","author":"J Owczarek","year":"2005","unstructured":"Owczarek J, Jasi\u0144ska M, Orszulak-Michalak D. Drug-induced myopathies. An overview of the possible mechanisms. Pharmacol Rep. 2005;57(1):23\u201334.","journal-title":"Pharmacol Rep"},{"issue":"4","key":"2086_CR191","doi-asserted-by":"publisher","first-page":"396","DOI":"10.14310\/horm.2002.1760","volume":"16","author":"MC Ponziani","year":"2017","unstructured":"Ponziani MC, Karamouzis I, Mele C, et al. Baseline glucose homeostasis predicts the new onset of diabetes during statin therapy: a retrospective study in real life. Hormones (Athens). 2017;16(4):396\u2013404. https:\/\/doi.org\/10.14310\/horm.2002.1760.","journal-title":"Hormones (Athens)"},{"issue":"1","key":"2086_CR192","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41533-019-0150-x","volume":"29","author":"DB Price","year":"2019","unstructured":"Price DB, Voorham J, Brusselle G, et al. Inhaled corticosteroids in COPD and onset of type 2 diabetes and osteoporosis: matched cohort study. NPJ Prim Care Respir Med. 2019;29(1):38. https:\/\/doi.org\/10.1038\/s41533-019-0150-x.","journal-title":"NPJ Prim Care Respir Med."},{"issue":"5","key":"2086_CR193","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1159\/000067466","volume":"67","author":"PJ Sullivan","year":"2000","unstructured":"Sullivan PJ, Jafar ZH, Harbinson PL, et al. Platelet dynamics following allergen challenge in allergic asthmatics. Respiration. 2000;67(5):514\u20137. https:\/\/doi.org\/10.1159\/000067466.","journal-title":"Respiration"},{"key":"2086_CR194","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.846055","volume":"13","author":"M Yue","year":"2022","unstructured":"Yue M, Hu M, Fu F, et al. Emerging roles of platelets in allergic asthma. Front Immunol. 2022;13: 846055. https:\/\/doi.org\/10.3389\/fimmu.2022.846055.","journal-title":"Front Immunol"},{"issue":"8","key":"2086_CR195","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.3390\/cells10082038","volume":"10","author":"L Luo","year":"2021","unstructured":"Luo L, Zhang J, Lee J, et al. Platelets, not an insignificant player in development of allergic asthma. Cells. 2021;10(8):2038. https:\/\/doi.org\/10.3390\/cells10082038.","journal-title":"Cells"},{"issue":"161","key":"2086_CR196","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0062-2021","volume":"30","author":"M Chebbo","year":"2021","unstructured":"Chebbo M, Duez C, Alessi MC, et al. Platelets: a potential role in chronic respiratory diseases? Eur Respir Rev. 2021;30(161): 210062. https:\/\/doi.org\/10.1183\/16000617.0062-2021.","journal-title":"Eur Respir Rev"},{"issue":"9","key":"2086_CR197","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1093\/cvr\/cvab003","volume":"117","author":"L Badimon","year":"2021","unstructured":"Badimon L, Vilahur G, Rocca B, et al. The key contribution of platelet and vascular arachidonic acid metabolism to the pathophysiology of atherothrombosis. Cardiovasc Res. 2021;117(9):2001\u201315. https:\/\/doi.org\/10.1093\/cvr\/cvab003.","journal-title":"Cardiovasc Res"},{"issue":"3","key":"2086_CR198","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3390\/medsci7030045","volume":"7","author":"KL Li","year":"2019","unstructured":"Li KL, Lee AY, Abuzeid WM. Aspirin exacerbated respiratory disease: epidemiology, pathophysiology, and management. Med Sci (Basel). 2019;7(3):45. https:\/\/doi.org\/10.3390\/medsci7030045.","journal-title":"Med Sci (Basel)."},{"issue":"2","key":"2086_CR199","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jaci.2022.08.021","volume":"151","author":"TM Laidlaw","year":"2023","unstructured":"Laidlaw TM, Boyce JA. Updates on immune mechanisms in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2023;151(2):301\u20139. https:\/\/doi.org\/10.1016\/j.jaci.2022.08.021.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"2086_CR200","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.jaci.2014.08.020","volume":"135","author":"JP Rajan","year":"2015","unstructured":"Rajan JP, Wineinger NE, Stevenson DD, et al. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature. J Allergy Clin Immunol. 2015;135(3):676\u201381. https:\/\/doi.org\/10.1016\/j.jaci.2014.08.020.","journal-title":"J Allergy Clin Immunol"},{"issue":"7437","key":"2086_CR201","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1136\/bmj.328.7437.434","volume":"328","author":"C Jenkins","year":"2004","unstructured":"Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ. 2004;328(7437):434. https:\/\/doi.org\/10.1136\/bmj.328.7437.434.","journal-title":"BMJ"},{"issue":"2","key":"2086_CR202","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40119-022-00255-9","volume":"11","author":"RA Thakker","year":"2022","unstructured":"Thakker RA, Salazar L, Jazar DA, et al. Coronary artery disease and aspirin intolerance: background and insights on current management. Cardiol Ther. 2022;11(2):175\u201383. https:\/\/doi.org\/10.1007\/s40119-022-00255-9.","journal-title":"Cardiol Ther."},{"issue":"1","key":"2086_CR203","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/jth.12779","volume":"13","author":"F Lussana","year":"2015","unstructured":"Lussana F, Di Marco F, Terraneo S, et al. Effect of prasugrel in patients with asthma: results of PRINA, a randomized, double-blind, placebo-controlled, cross-over study. J Thromb Haemost. 2015;13(1):136\u201341. https:\/\/doi.org\/10.1111\/jth.12779.","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2086_CR204","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1185\/03007995.2013.781502","volume":"29","author":"K Butler","year":"2013","unstructured":"Butler K, Maya J, Teng R. Effect of ticagrelor on pulmonary function in healthy elderly volunteers and asthma or chronic obstructive pulmonary disease patients. Curr Med Res Opin. 2013;29(5):569\u201377. https:\/\/doi.org\/10.1185\/03007995.2013.781502.","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"2086_CR205","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1111\/jcmm.14239","volume":"23","author":"HKT Trinh","year":"2019","unstructured":"Trinh HKT, Nguyen TVT, Choi Y, et al. The synergistic effects of clopidogrel with montelukast may be beneficial for asthma treatment. J Cell Mol Med. 2019;23(5):3441\u201350. https:\/\/doi.org\/10.1111\/jcmm.14239.","journal-title":"J Cell Mol Med"},{"issue":"4","key":"2086_CR206","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/bph.16039","volume":"181","author":"KL Arkless","year":"2024","unstructured":"Arkless KL, Pan D, Shankar-Hari M, et al. Stimulation of platelet P2Y1 receptors by different endogenous nucleotides leads to functional selectivity via biased signalling. Br J Pharmacol. 2024;181(4):564\u201379. https:\/\/doi.org\/10.1111\/bph.16039.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"2086_CR207","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1517\/13543784.11.2.275","volume":"11","author":"JM Dogn\u00e9","year":"2002","unstructured":"Dogn\u00e9 JM, de Leval X, Benoit P, et al. Therapeutic potential of thromboxane inhibitors in asthma. Expert Opin Investig Drugs. 2002;11(2):275\u201381. https:\/\/doi.org\/10.1517\/13543784.11.2.275.","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"2086_CR208","doi-asserted-by":"publisher","first-page":"16","DOI":"10.4103\/lungindia.lungindia_226_17","volume":"35","author":"R Magazine","year":"2018","unstructured":"Magazine R, Surendra VU, Chogtu B. Comparison of oral montelukast with oral ozagrel in acute asthma: a randomized, double-blind, placebo-controlled study. Lung India. 2018;35(1):16\u201320. https:\/\/doi.org\/10.4103\/lungindia.lungindia_226_17.","journal-title":"Lung India"},{"issue":"2","key":"2086_CR209","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1139\/cjpp-2014-0364","volume":"93","author":"JM Hernandez","year":"2015","unstructured":"Hernandez JM, Janssen LJ. Revisiting the usefulness of thromboxane-A2 modulation in the treatment of bronchoconstriction in asthma. Can J Physiol Pharmacol. 2015;93(2):111\u20137. https:\/\/doi.org\/10.1139\/cjpp-2014-0364.","journal-title":"Can J Physiol Pharmacol"},{"issue":"6","key":"2086_CR210","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1177\/1074248414530508","volume":"19","author":"T Godfraind","year":"2014","unstructured":"Godfraind T. Calcium channel blockers in cardiovascular pharmacotherapy. J Cardiovasc Pharmacol Ther. 2014;19(6):501\u201315. https:\/\/doi.org\/10.1177\/1074248414530508.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"1","key":"2086_CR211","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1183\/09031936.00147706","volume":"30","author":"S Hirota","year":"2007","unstructured":"Hirota S, Helli P, Janssen LJ. Ionic mechanisms and Ca2+ handling in airway smooth muscle. Eur Respir J. 2007;30(1):114\u201333. https:\/\/doi.org\/10.1183\/09031936.00147706.","journal-title":"Eur Respir J"},{"issue":"3","key":"2086_CR212","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1046\/j.0306-5251.2001.01560.x","volume":"53","author":"MA Twiss","year":"2002","unstructured":"Twiss MA, Harman E, Chesrown S, et al. Efficacy of calcium channel blockers as maintenance therapy for asthma. Br J Clin Pharmacol. 2002;53(3):243\u20139. https:\/\/doi.org\/10.1046\/j.0306-5251.2001.01560.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"2086_CR213","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.anai.2017.08.013","volume":"119","author":"KY Chiu","year":"2017","unstructured":"Chiu KY, Li JG, Lin Y. Calcium channel blockers for lung function improvement in asthma: a systematic review and meta-analysis. Ann Allergy Asthma Immunol. 2017;119(6):518\u201323. https:\/\/doi.org\/10.1016\/j.anai.2017.08.013.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"2086_CR214","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.anai.2021.02.029","volume":"126","author":"R Tsuzuki","year":"2021","unstructured":"Tsuzuki R, To M, Yamawaki S, et al. Inhibitory effect of calcium channel blockers on the deterioration of lung function in adult-onset asthma. Ann Allergy Asthma Immunol. 2021;126(6):731\u20133. https:\/\/doi.org\/10.1016\/j.anai.2021.02.029.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"2086_CR215","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.anai.2021.10.030","volume":"128","author":"JM Martinez Manzano","year":"2022","unstructured":"Martinez Manzano JM, Lo KB, Jarrett SA, et al. Angioedema associated with the use of dihydropyridine calcium channel blockers. A case series. Ann Allergy Asthma Immunol. 2022;128(2):228\u20139. https:\/\/doi.org\/10.1016\/j.anai.2021.10.030.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6 Pt 1","key":"2086_CR216","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/0002-9343(89)90438-5","volume":"86","author":"BJ Lipworth","year":"1989","unstructured":"Lipworth BJ, McDevitt DG, Struthers AD. Prior treatment with diuretic augments the hypokalemic and electrocardiographic effects of inhaled albuterol. Am J Med. 1989;86(6 Pt 1):653\u20137. https:\/\/doi.org\/10.1016\/0002-9343(89)90438-5.","journal-title":"Am J Med"},{"key":"2086_CR217","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2147\/IBPC.S33982","volume":"6","author":"D Chandy","year":"2013","unstructured":"Chandy D, Aronow WS, Banach M. Current perspectives on treatment of hypertensive patients with chronic obstructive pulmonary disease. Integr Blood Press Control. 2013;6:101\u20139. https:\/\/doi.org\/10.2147\/IBPC.S33982.","journal-title":"Integr Blood Press Control."},{"issue":"4","key":"2086_CR218","doi-asserted-by":"publisher","first-page":"R135","DOI":"10.1530\/EC-18-0109","volume":"7","author":"E Kardalas","year":"2018","unstructured":"Kardalas E, Paschou SA, Anagnostis P, et al. Hypokalemia: a clinical update. Endocr Connect. 2018;7(4):R135\u201346. https:\/\/doi.org\/10.1530\/EC-18-0109.","journal-title":"Endocr Connect"},{"issue":"4","key":"2086_CR219","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3390\/jcm8040563","volume":"8","author":"I Vasileiadis","year":"2019","unstructured":"Vasileiadis I, Alevrakis E, Ampelioti S, et al. Acid-base disturbances in patients with asthma: a literature review and comments on their pathophysiology. J Clin Med. 2019;8(4):563. https:\/\/doi.org\/10.3390\/jcm8040563.","journal-title":"J Clin Med"},{"issue":"5","key":"2086_CR220","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1517\/14656566.2014.879117","volume":"15","author":"J Tamargo","year":"2014","unstructured":"Tamargo J, Segura J, Ruilope LM. Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents. Expert Opin Pharmacother. 2014;15(5):605\u201321. https:\/\/doi.org\/10.1517\/14656566.2014.879117.","journal-title":"Expert Opin Pharmacother"},{"issue":"7","key":"2086_CR221","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.ejheart.2006.01.010","volume":"8","author":"FH Rutten","year":"2006","unstructured":"Rutten FH, Cramer MJ, Lammers JW, et al. Heart failure and chronic obstructive pulmonary disease: An ignored combination? Eur J Heart Fail. 2006;8(7):706\u201311. https:\/\/doi.org\/10.1016\/j.ejheart.2006.01.010.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"2086_CR222","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1053\/j.ajkd.2010.01.020","volume":"56","author":"BF Palmer","year":"2010","unstructured":"Palmer BF. A physiologic-based approach to the evaluation of a patient with hyperkalemia. Am J Kidney Dis. 2010;56(2):387\u201393. https:\/\/doi.org\/10.1053\/j.ajkd.2010.01.020.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"2086_CR223","doi-asserted-by":"publisher","first-page":"931","DOI":"10.3892\/ijmm.2012.1072","volume":"30","author":"Z Tang","year":"2012","unstructured":"Tang Z, Jiang L, Peng J, et al. PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-\u03baB activation in THP-1-derived macrophages. Int J Mol Med. 2012;30(4):931\u20138. https:\/\/doi.org\/10.3892\/ijmm.2012.1072.","journal-title":"Int J Mol Med"},{"issue":"4","key":"2086_CR224","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2024.100899","volume":"17","author":"Y Xu","year":"2024","unstructured":"Xu Y, Li Y. Association between lipid-lowering drugs and allergic diseases: a Mendelian randomization study. World Allergy Organ J. 2024;17(4): 100899. https:\/\/doi.org\/10.1016\/j.waojou.2024.100899.","journal-title":"World Allergy Organ J"},{"issue":"1","key":"2086_CR225","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12931-024-02842-x","volume":"25","author":"L Liang","year":"2024","unstructured":"Liang L, Chung SI, Guon TE, Park KH, Lee JH, Park JW. Statin administration or blocking PCSK9 alleviates airway hyperresponsiveness and lung fibrosis in high-fat diet-induced obese mice. Respir Res. 2024;25(1):213. https:\/\/doi.org\/10.1186\/s12931-024-02842-x.","journal-title":"Respir Res"},{"issue":"1","key":"2086_CR226","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13075-023-03122-7","volume":"25","author":"W Xie","year":"2023","unstructured":"Xie W, Li J, Du H, Xia J. Causal relationship between PCSK9 inhibitor and autoimmune diseases: a drug target Mendelian randomization study. Arthritis Res Ther. 2023;25(1):148. https:\/\/doi.org\/10.1186\/s13075-023-03122-7.","journal-title":"Arthritis Res Ther"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02086-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-024-02086-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02086-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T23:05:23Z","timestamp":1735859123000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-024-02086-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,26]]},"references-count":226,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["2086"],"URL":"https:\/\/doi.org\/10.1007\/s40265-024-02086-5","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,26]]},"assertion":[{"value":"14 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Universit\u00e0 degli Studi di Roma Tor Vergata within the CRUI-CARE Agreement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no financial or non-financial relationships or activities concerning this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors were involved in the initial conception of the manuscript. M.C. and C.P.P. led the drafting and coordinated the revisions of the manuscript among all authors. N.A.H., L.C., M.G.M., and P.R. critically revised the content on their areas of expertise. All authors approved the final draft.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}